Conditions: Prostate Cancer
Keywords: Prostate Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 42
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.

Detailed description:
This is a Multi-center, open-label study to evaluate testosterone recovery after six months of neo-adjuvant treatment with ELIGARD (TM) 22.5mg used with Radiation Therapy in patients with TNM T1, T2 or T3A adenocarcinoma of the prostate. The 60 patients will receive two subcutaneous administration of ELIGARD (TM) 22.5mg (Baseline and Month 3) and receive Radiation Therapy (Month 2-4).

Arms:
arm 1: Eligard (TM) administered 22.5mg

Interventions: intervention 1: Eligard (TM)
Intervention descriptions: intervention 1: Eligard (TM) 22.5 mg administered at baseline and Month 3

Protocol document: